03.11.2016 Evonik Industries AG  DE000EVNK013

DGAP-News: Evonik Industries AG: Evonik submits bid for METEX methionine technology platform


 
DGAP-News: Evonik Industries AG / Key word(s): Mergers & Acquisitions Evonik Industries AG: Evonik submits bid for METEX methionine technology platform 03.11.2016 / 17:45 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Evonik submits bid for METEX methionine technology platform - Evonik to strengthen its biotechnology platform - Binding bid for METEX fermentation methionine technology - Both parties agreed to exclusivity and aim for a timely conclusion of the agreement Essen, Germany. Amino acids produced by fermentation are an important pillar of Evonik's product portfolio for sustainable animal nutrition. The production processes for Biolys(R) (lysine), ThreAMINO(R) (threonine) and TrypAMINO(R) (tryptophane) have been made continuously more efficient over the past years and the portfolio was just recently enlarged by launching ValAMINO(R) (valine). In order to strengthen its biotechnology platform Evonik intends the acquisition of a large technology package from the French company METabolic EXplorer (METEX) and has submitted a binding offer on October 27th. The bid is subject to approval by Evonik committees. METEX, which is headquartered in Clermont-Ferrand (France), has succeeded in developing a fermentation process for manufacturing methionine. The binding Evonik offer includes the takeover of METEX's entire methionine technology as well as patents, essential bacteria strains, and the inoLaTM brand. These are to be transferred to Evonik after closing. The transaction also includes a license agreement for the continued use of base technology by METEX. The companies also intend to explore the possibility of a research cooperation on the technological development of biotechnologically produced amino acids. The companies are planning a timely conclusion of the agreement and have agreed to exclusivity and not to disclose any information on the next steps until the agreement has been signed. Founded in 1999 the biotechnology company METabolic EXplorer specializes in the development of biotechnology production processes for bio-based substances that are used in a wide variety of daily everyday products such as textile fibers and feed additives. Company information Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion. About Nutrition & Care The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around EUR4.9 billion in 2015. Disclaimer In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Contact: Tim Lange Head of Investor Relations +49 201 177-3150 tim.lange@evonik.com Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Fax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Christian Kullmann, Deputy Chairman Dr. Ralph Sven Kaufmann Thomas Wessel Ute Wolf Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474 --------------------------------------------------------------------------- 03.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone: +49 (0) 201 177-01 Fax: +49 (0) 201 177-3475 E-mail: investor-relations@evonik.com Internet: www.evonik.com ISIN: DE000EVNK013, XS0911405784 WKN: EVNK01, A1TM7T Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxemburg End of News DGAP News Service --------------------------------------------------------------------------- 516961 03.11.2016


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 12.874,00 12.917,00 13.507,00 12.732,00 14.419,00 15.024,00 13.108,00 13.140,00
EBITDA1,2 1.995,00 1.822,00 2.465,00 2.165,00 2.357,00 2.150,00 2.153,00 2.140,00
EBITDA-Marge3 15,50 14,11 18,25 17,00 16,35 14,31 16,43 16,29
EBIT1,4 1.424,00 1.046,00 1.644,00 1.298,00 1.229,00 1.367,00 1.080,00 0,00
EBIT-Marge5 11,06 8,10 12,17 10,19 8,52 9,10 8,24 0,00
Jahresüberschuss1 2.054,00 581,00 1.019,00 762,00 734,00 954,00 2.127,00 0,00
Netto-Marge6 15,95 4,50 7,54 5,98 5,09 6,35 16,23 0,00
Cashflow1,7 1.083,00 1.066,00 1.968,00 1.758,00 1.551,00 1.704,00 1.321,00 0,00
Ergebnis je Aktie8 1,78 1,22 2,13 1,81 1,54 2,00 4,52 1,65
Dividende8 1,00 1,00 1,15 1,15 1,15 1,15 1,15 0,75
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evonik Industries
WKN Kurs in € Einschätzung Börsenwert in Mio. €
EVNK01 22,020 Halten 10.261,32
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
11,59 14,98 0,773 10,17
KBV KCV KUV EV/EBITDA
1,22 7,77 0,78 7,625
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
1,15 0,75 5,22 31.08.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2020 04.08.2020 03.11.2020 04.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-8,26% -6,40% -19,07% -2,39%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evonik Industries AG  ISIN: DE000EVNK013 können Sie bei DGAP abrufen

Chemie , EVNK01 , EVK , XETR:EVK